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Major  histocompatibility  complex  class  I proteins  (MHC-I)  load short  peptides  derived  from  proteoly-
tic  cleavage  of  endogenous  proteins  in any  cell of  the body,  in  a process  termed  antigen  processing
and  presentation.  When  the  source  proteins  are  altered  self  or encoded  by  a pathogen,  recognition  of
peptide/MHC-I  complexes  at the  plasma  membrane  leads  to CD8+ T-lymphocyte  responses  that  clear
infections  and  probably  underlie  tumor  immune  surveillance.  On  the  other  hand,  presentation  of  self  pep-
tides may  cause  some  types  of autoimmunity.  The  peptides  that  are  presented  determine  the  speciﬁcity
and  efﬁciency  of pathogen  clearance  or,  conversely,  of immunopathology.  In this review  we  highlight
the  growing  number  of  peptidases  which,  as  a by-product  of their  regular  activity,  can  generate  peptide
epitopes  for  immune  surveillance.  These  ∼20 peptidases  collectively  behave  as  a guerrilla  army  partner-
ing  with  the  regular  proteasome  army  in generating  a variety  of peptides  for presentation  by MHC-I  and
thus  optimally  signaling  infection.
© 2015  The  Authors.  Published  by Elsevier  Ltd.  This  is an  open  access  article  under  the  CC  BY-NC-ND
license  (http://creativecommons.org/licenses/by-nc-nd/4.0/).
1. Introduction
Protein degradation pathways process misfolded or aberrant
proteins, avoid their accumulation in the cell and maintain protein
turnover. Side products of these essential pathways are peptides,
some of which can bind MHC-I molecules. When peptides derive
from pathogen or tumor proteins, peptide-loaded MHC-I molecules
at the cell surface induce a proper CD8+ T-lymphocyte immune
response; in any cell type, presentation of self peptides should not
induce a response. In addition, peptidases can also cleave within
peptide epitopes, destroying them, a process that can limit anti-
gen presentation. Which peptides are targeted by the immune
response, and which peptidases have generated them, can directly
inﬂuence the efﬁcacy of naïve T-cell activation by professional
antigen presenting cells, as well as the subsequent efﬁciency of
detection and elimination by CD8+ cytotoxic T lymphocytes of
Abbreviations: aa, amino acid; Ct, carboxy terminus; ER, endoplasmic reticu-
lum; MHC-I, major histocompatibility complex class I; Nt, amino terminus; TAP,
transporter associated with antigen processing.
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infected cells or tumors that are presenting pathogen or altered
peptides.
Antigen processing and presentation takes place in homeostasis
in any cell of the body. It involves generation of precursor pep-
tides by proteolytic cleavage typically in the cytosol, transport by
the transporter associated with antigen processing (TAP) into the
lumen of the endoplasmic reticulum (ER), proteolytic trimming to
a typical length of 8–10 amino acids (aa), binding to nascent MHC-I
molecules, peptide/MHC-I complex display at the cell surface and
recognition by the T-cell receptor of CD8+ cytotoxic T lymphocytes.
Antigen presentation by professional antigen presenting cells can
also include peptides derived from exogenous proteins in a process
termed cross presentation.
The major peptidase in the cell is the multicatalytic, multimeric
and highly regulated proteasome, located in cytosol and nucleus. Its
long-known role in antigen processing and presentation by MHC-I
of many epitopes (Kloetzel and Ossendorp, 2004) is highlighted
(i) by the marked inhibition of antigen presentation when it is
inhibited, speciﬁcally of the generation of the carboxyl terminus
(Ct) of epitopes, (ii) by its modulation by interferon- and thereby
of the epitopes presented, and (iii) by its prominent degradation of
defective ribosomal products (DRiPs) for fast antigen presentation
(Antón and Yewdell, 2014).
We  will brieﬂy address in this review the current knowledge
about non-proteasomal exopeptidases and endopeptidases and
their role in MHC-I antigen presentation to CD8+ cytotoxic T lym-
phocytes. Additional references can be found in the Supplemental
http://dx.doi.org/10.1016/j.molimm.2015.04.014
0161-5890/© 2015 The Authors. Published by Elsevier Ltd. This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
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Table. Following the antigen processing route from the cytosol,
through the ER via TAP, into the exocytic route, till the plasma
membrane, we will ﬁnd amino exopeptidases, endopeptidases and
carboxy exopeptidases. As cell biology goes, most have a primary
role in other cellular processes, but can as a side effect also generate
peptides for immunosurveillance.
A set of ∼15 degradative peptidases localized in the cytosol
and the secretory pathway cooperate with proteasomes in anti-
gen processing, by pre- or post-processing antigens from longer
proteasomal precursors or products (Table 1, ‘PD’). Due to this
cooperative role in processing given epitopes, ﬁnal epitope pre-
sentation is inhibited by proteasome inhibitors; the contribution
of these peptidases thus often passes undetected while the role
of proteasomes may  be overestimated. Interestingly, ∼8 additional
peptidases process antigens independently of the proteasome and
eventually generate MHC-I mature epitopes (Table 1, ‘PI’); they
are mostly endopeptidases, and include TPPII, Caspases 5 and 10,
IDE, SP, SPP, Furin and Cathepsin S; they are found in cytosol
and in secretory compartments, and the latter often contribute to
TAP-independent antigen presentation. Around 10 peptidases are
involved in cross presentation by MHC-I of antigens from exoge-
nous sources; those that contribute (Caspases 3 and 8, ERAP1, ACE,
SP, Furin, Cathepsin S and IRAP) are mostly located in vesicular
compartments, while the cytosolic ones (DPP-III, TPPII, TOP) mostly
interfere with cross presentation.
Mice deﬁcient for these peptidases have been studied. In some
cases, this has not been possible for lack of a mouse ortholog (Cas-
pases 5 and 10, ERAP2) or because the deﬁciency is lethal (signal
peptidase, furin). Most animal models, even with combined deﬁ-
ciencies, do not show global effects in MHC  class I expression nor
impairment in antigen presentation (LAP, Blmh, PSA, IDE). In some
cases, (i) speciﬁc antigens have been shown in vivo to require one
of these peptidases for direct or cross presentation (ERAP1, ACE,
Cathepsin S, IRAP, Caspases 3 and 8) or to be degraded by them
(TPPII, ERAP1, ACE, TOP), (ii) the peptidase decreases (PSA in den-
dritic cells, TPPII, ACE) or increases (ERAP1, SPP, PC7) global MHC-I
levels in vivo, or (iii) the peptidase more globally shapes the in vivo
peptide and TCR repertoire (ERAP1, ACE).
Evidence for peptidase involvement reaches variable degrees
of certainty: trimming of synthetic extended peptides in cell-free
assays with cell extracts or with puriﬁed peptidases, broadly or
very speciﬁc interference with function in cell culture (employ-
ing chemical inhibitors, interfering RNA or gene deﬁcient cells),
cell culture analysis of constructs with cleavage site mutations or
miniprotein or other constructs and, ﬁnally, in vivo assays. In vivo
and cell culture assays provide general proof of involvement, while
ascription of potential amino-terminal (Nt) or Ct trimming activi-
ties is mostly based solely on testing putative precursor peptides
in vitro (Table 1).
Occasional failures in ﬁnding a peptidase responsible for the
generation of proteasome inhibitor-resistant epitopes have not a
unique explanation: (i) the inhibition of the proteasome may  not
be complete (Kisselev et al., 2006) and the residual activity sufﬁce
to generate the epitope, (ii) the altered pattern of the proteasomal
activity caused by its inhibition may  be able to generate the epitope
(Wherry et al., 2006), and (iii) other unknown peptidases may  be
responsible for epitope generation when the proteasome activity
is impaired.
2. Cytosolic aminopeptidases and endopeptidases involved
in antigen processing
The cytosol is a highly degradative environment, and harbors
proteasomes as well as many peptidases that rapidly degrade pep-
tides into aa, a key process for cell survival. In living cells, labeled
peptides are degraded within seconds by aminopeptidases (Reits
et al., 2003). Cytosolic aminopeptidases can trim the Nt of extended
epitope precursors, resulting either in the generation of the correct
MHC-I epitope Nt, or in its destruction. Most proteasomal products
require further proteolytic trimming in order to generate 8–10 aa-
long epitopes with the correct Nt, but a 15-aa-long peptide with 6
extended aa on its Nt can also constitute a natural epitope presented
to CD8+ T cells (Samino et al., 2006). Several aminopeptidases,
such as leucine aminopeptidase (LAP), bleomycin hydrolase (Blmh)
or puromycin-sensitive aminopeptidase (PSA), participate in antigen
processing mostly in cell-free assays, while dipeptidyl-peptidase III
(DPP-III) interferes with cross-presentation. Tripeptidyl-peptidase II
(TPPII) is an aminopeptidase involved in cell division and apoptosis
or diseases like obesity and cancer. TPPII can process an epitope
independently of the proteasome, as well as 3 more epitopes for
which the proteasomal activity is detrimental (Seifert et al., 2003).
As peptides longer than 15 aa are processed mainly by TPPII rather
than by other aminopeptidases, TPPII is currently understood as a
co-operator, rather than a substitute, for antigen processing of rare
long proteasomal products. Results in TPPII-deﬁcient mice suggest
a slightly destructive global role of TPPII in MHC-I epitope pro-
duction and interference with cross presentation of an exogenous
antigen.
Several studies describe cytosolic complementary endopepti-
dases in antigen processing for MHC-I, and these often can process
antigens independently of proteasomes. The thimet oligopeptidase
(TOP) is an endopeptidase whose main action results in epitope
degradation (Saric et al., 2001), to the extent that it prevents cross
presentation of necrotic cells, although it can also generate precur-
sor peptides and cleave peptides generating the Ct of an epitope
(Kessler et al., 2011). Caspases are inﬂammatory and apoptotic
endopeptidases. Caspases 5 and 10 participate in a proteasome-
independent manner in the production of a viral epitope that can
also be similarly processed by proteasomes (López et al., 2010). Cas-
pases 3 and 8 generate substrates from self proteins in apoptotic
cells for proteasome-dependent cross presentation by dendritic
cells. The insulin-degrading enzyme (IDE) endopeptidase cleaves
insulin and contributes to the proteasome-independent production
of a tumor epitope (Parmentier et al., 2010). Nardilysin endopepti-
dase participates in the generation of precursor peptides of a tumor
protein and in producing the correct Nt of a viral epitope (Kessler
et al., 2011).
3. ER exopeptidases and endopeptidases associated with
antigen processing
Compared to the cytosol, the ER shows low proteolytic activity.
The most prominent ER proteolytic step in the antigen presentation
pathway is trimming by aminopeptidases that remove Nt ﬂanking
residues from antigenic peptide precursors. The result of the com-
bined sequential aminopeptidase activity in the cytosol and in the
ER has been estimated by analyzing the frequency of aa in the Nt
ﬂank of many epitopes, to deﬁne a ‘Nt processing sequence motif’
(Schatz et al., 2008).
ER aminopeptidase ERAP1 is an interferon--inducible enzyme
very relevant for antigen processing, emphasized by the existence
of ERAP1 inhibitors in cytomegalovirus (Kim et al., 2011). ERAP1
products in vitro are rarely shorter than 8 or 9 aa, the proper
length for binding to MHC-I molecules (Serwold et al., 2002; York
et al., 2002). This is consistent with the length preference of TAP
transporter to translocate peptides to the ER and of MHC-I for
peptide binding. Several MHC-I allotypes prefer proline in epitope
position 2 as binding motif; however, TAP cannot transport these
ﬁnal peptides, requiring the transport of Nt extended precursors.
Among the strongest evidence for ER trimming is the observation
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Table  1
Peptidases involved in antigen processing for presentation by MHC-I to CD8+ T lymphocytes.
Peptidases Peptidase class and
speciﬁcity
Evidence of involvement in antigen processing for presentation by MHC-Ia,b,c
Leucine aminopeptidase (LAP) Metalloaminopeptidase. It
prefers Nt hydrophobic
aminoacids.
(T): IFN- induced Nt trimming by LAP of synthetic peptide in cell-free assay.
Bleomycin hydrolase (Blmh) Cysteine aminopeptidase.
It  has no speciﬁcity for
substrate sequence.
(T): Inhibition of antigen presentation in infected cells by a broadly speciﬁc compound,
AAF-cmk; Nt trimming by Blmh of a VSV peptide in vitro; Blmh affects surface expression of
certain human MHC-I allotypes.
Puromycin-sensitive
aminopeptidase (PSA)
Zinc-binding
metallo-aminopeptidase. It
prefers Nt Ala, Leu, Phe,
Met  and basic aa.
(T)(PD): Nt trimming by PSA of RU1 peptide in cell-free assays sequentially after TPPII;
inhibition of antigen presentation by broadly speciﬁc compound, AAF-cmk, in infected and
tumoral cells; Nt trimming of a VSV peptide and a RU1 peptide in vitro; PSA affects surface
expression of certain human MHC-I allotypes. (In vivo): harmful for MHC-I surface expression
in  dendritic cells.
Dipeptidyl-peptidase III (DPP-III) Zinc-binding
metalloaminopeptidase. It
cleaves Nt dibasic
dipeptides mainly from
oligopeptides.
(PD): exogenous addition of DPP-III to necrotic cells prevents cross presentation of an Ova
epitope by dendritic cells in vitro and in vivo. DPP-III is not involved in direct presentation.
Tripeptidyl-peptidase II (TPPII) Serine aminopeptidase. It
removes tripeptides from
Nt of substrates unless it
ﬁnds a Pro. It also acts as a
trypsin-like endopeptidase.
(PI): Inhibition by selective compound, butabindide, and interfering RNA in cell culture
indicates TPPII processes an EBV LMP1 epitope, and other epitopes that are degraded by
proteasomes from HIV nef, EBV LMP1 and inﬂuenza virus nucleoprotein. (T): It processes large
proteasomal products. It cooperates with PSA in Nt trimming of RU1 peptides in cell-free
assays; Nt trimming in vitro. (In vivo): TPPII is harmful for direct and for cross presentation of
an  Ova epitope; harmful for MHC-I surface expression.
Thimet oligopeptidase (TOP) Zinc-binding
metallo-endopeptidase. It
optimally cleaves
oligopeptides on the Ct of
Phe, Ala, or Arg.
(T): Inhibition by interfering RNA in cell culture indicates TOP processes two epitopes from
tumor proteins PRAME and MART, degrades Ova and EBV LMP1 epitope, and is harmful for
MHC-I surface expression; TOP generates in vitro Ct of PRAME and MART epitopes, one after
nardilysin. (PD, in vivo): in necrotic cells TOP prevents cross presentation of an Ova  epitope by
dendritic cells.
Caspases Cysteine endopeptidases.
They cleave at the Ct of Asp.
(PI): Inhibition by selective compound, z-VAD-cmk, and viral inhibitor B13R in cell culture
indicates caspases process a CMV epitope; in vitro caspase 5 produces Ct of the epitope and
caspase 10 creates Nt and Ct. (PD): Inhibition by selective compounds indicates caspases 3 and
8  generate in apoptotic cells substrates for proteasome-dependent cross presentation by
dendritic cells of self antigens.
Insulin-degrading enzyme (IDE) Zinc-binding
metallo-endopeptidase. It
cleaves preferentially
insulin and substrates with
a  sheet conformation.
(PI): Inhibition by a battery of broadly speciﬁc compounds and interfering RNA in cell culture
indicates IDE processes an epitope from MAGE-A3; in vitro IDE generates Nt and Ct of the
epitope.
Nardilysin Zinc-binding
metallo-endopeptidase. It
recognizes dibasic motifs.
(PD): Inhibition by interfering RNA in cell culture indicates Nardilysin processes two epitopes
from tumor protein PRAME and EBV EBNA3 C; Nardilysin cooperates in vitro with TOP for
PRAME, and generates Nt of the EBNA3 C epitope.
Endoplasmic reticulum
aminopeptidase 1 (ERAP1)
Zinc-binding
metallo-aminopeptidase. It
prefers Nt hydrophobic
and aromatic aa, and aa
with long aliphatic side
chains. It does not cleave
Pro. Its optimal substrates
are 9–16 aa-long peptides,
and its products are rarely
shorter than 8 or 9 aa.
(T): Inhibition by selective compound, leucinethiol, by interfering RNA and by gene deletion in
cell culture indicates ERAP1 processes many epitopes; destruction of other epitopes; net
contribution to MHC-I surface expression; exact generation of Nt of epitopes in cell culture,
cell-free assays and in vitro. It cooperates with ERAP2 in trimming proteasome products; it
trims precursors produced by other peptidases in this list. (In vivo): it contributes to cross
presentation; it shapes the CD8+ T lymphocyte repertoire.
Endoplasmic reticulum
aminopeptidase 2 (ERAP2)
Zinc-binding
metallo-aminopeptidase. It
prefers Nt positively
charged aa, followed by aa
with short hydrophobic
side chains.
(T): Inhibition by selective compound, leucinethiol, and by interfering RNA in cell culture
indicates ERAP2 processes epitopes; exact generation of Nt of epitopes and cooperation with
ERAP1 in cell culture and in vitro.
Angiotensin converting enzyme
(ACE)
Zinc-binding
metallo-carboxypeptidase.
It cleaves Ct dipeptides
from oligopeptides with
wide substrate speciﬁcity
(T): Inhibition by selective compound, ramipril, by interfering RNA and by gene deletion in cell
culture indicates ACE processes 3 self epitopes and degrades 3 self epitopes; it shapes the
MHC-I peptide repertoire; harmful for rate of MHC-I surface expression; exact generation of Ct
of  epitopes in vitro; it enhances cross presentation of an Ova epitope. (In vivo): ACE processes 2
epitopes and degrades 1 epitope; it shapes the CD8+ T lymphocyte repertoire.
Signal  peptidase (SP) Serine endopeptidase. It
cleaves at the Ct of small
non-polar aa at the Ct of
signal sequences.
(PI): mutation of SP cleavage site indicates SP processes an epitope from MHC-I. (PI): mutation
of  SP cleavage site indicates it contributes to cross presentation of ricin-delivered epitopes
independently of TAP. (PD): It degrades an epitope from prostate stem cell antigen; mass
spectrometry data suggest TAP-independent generation by SP of exact Ct of HLA-A2-presented
self  peptides.
Signal peptide peptidase (SPP) Aspartyl endopeptidase. It
cleaves within
transmembrane domains
and in signal sequences.
(PI): Inhibition by selective compound, z-(LL)2, and by interfering RNA in cell culture indicates
SPP  processes a Trh4 epitope; involved in MHC-I surface expression. (PD): Inhibition by
selective compound, z-(LL)2, in cell culture indicates SPP processes an epitope in preprolactin
signal peptide.
Furin Serine endopeptidase. It
cleaves preferentially after
polybasic residues.
(PI): Inhibition by selective compound, dec-RVKR-cmk, in cell culture indicates Furin
processes a CMV  epitope to ﬁnal size independently of TAP, probably in cooperation with
trimming amino- and carboxy-peptidases; TAP-independent Nt processing of Ova epitope
from a fusion protein.
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Table  1 (Continued)
Peptidases Peptidase class and
speciﬁcity
Evidence of involvement in antigen processing for presentation by MHC-Ia,b,c
Cathepsins Aspartyl endopeptidases.
Each cathepsin has its own
speciﬁcity. Cathepsin D and
S speciﬁcity is primarily
guided by residues in P2,
Leu or Asp for cathepsin D,
and aliphatic for cathepsin
S.
(PI): Inhibition by selective compound, pepstatin A, in cell culture indicates cathepsins process
Ova epitope from fusion proteins independently of TAP; cathepsin S in phagosomes needed for
cross presentation of Ova epitope; in vitro Nt and Ct processing of Ova epitope. (In vivo):
cathepsin S contributes to cross presentation of Ova epitope independently of TAP by a
vacuolar pathway.
Proprotein convertase 7 (PC7) Calcium-dependent serine
endopeptidase. It cleaves
preferentially after dibasic
residues.
Inhibition by interfering RNA indicates PC7 stabilizes MHC-I in cells without TAP and with
malfunctioning peptide loading complex; involved in shaping the MHC-I peptide repertoire; it
processes an exogenous EBV peptide precursor.
Insulin responsive aminopeptidase
(IRAP)
Zinc-binding
metallo-aminopeptidase. It
has a broad speciﬁcity,
roughly combining that of
ERAP1 and ERAP2.
(T): in vitro Nt trimming by IRAP of synthetic peptide; (PD): IRAP cross presents Ova beads in
cell  culture. (In vivo): IRAP contributes to cross presentation of particulate and soluble Ova and
a  SMCY male epitope. IRAP is not involved in direct presentation.
a T: trimming of precursor peptides. PI: ‘proteasome-independent’: antigen processing activity in the presence of proteasome inhibitors. PD: ‘proteasome-dependent’:
antigen processing activity in cooperation with proteasomes.
b CMV, cytomegalovirus, EBV, Epstein–Barr virus, HIV, human immunodeﬁciency virus, Ova, ovalbumin, VSV, vesicular stomatitis virus.
c Complete set of references can be found in the Supplemental Table.
that ERAP1 trimming stops at peptides with proline in position 2
and thus spares them for binding by MHC  I. Binding even of long
peptides to MHC-I prevents further trimming by ERAP1, although
there is an alternative model for post-binding trimming. Different
studies in cell culture and in vivo have shown the contribution of
ERAP1 not only in the generation but also in the destruction of
different epitopes (Serwold et al., 2002; York et al., 2002). There
is even an epitope that is only generated when ERAP1 activity is
impaired (Nagarajan et al., 2012). ERAP1 can also cooperate with
other non-proteasomal peptidases. ERAP1 is also involved in cross
presentation. In ERAP1-deﬁcient mice, MHC-I molecules expres-
sion is diminished and the CD8+ T-lymphocyte repertoire is altered,
indicating that trimming of precursors by ERAP1 is already occur-
ring during thymic selection (Hammer et al., 2006).
ERAP2 is interferon--inducible and can form dimeric com-
plexes with ERAP1 increasing the efﬁciency in cleaving precursors
(Saveanu et al., 2005).
Need in the exocytic pathway for carboxypeptidases or for
enzymes generating Ct for antigen presentation has been appre-
ciated since 1992 (Gil-Torregrosa et al., 1998; Henderson et al.,
1992; Wei  and Cresswell, 1992). Ct trimming has been variably
estimated for different epitopes to enhance antigen presenta-
tion by >1000-fold (Medina et al., 2009), or to contribute poorly
(Snyder et al., 1998), or not at all in rat cells (Powis et al., 1996).
Recent data indicate that angiotensin-converting enzyme (ACE), a
carboxy-dipeptidase, can generate the Ct of epitopes from peptides
pre-processed by the proteasome. As ERAP1, ACE-deﬁciency causes
a new repertoire of unique epitopes and T-lymphocyte speciﬁci-
ties (Shen et al., 2011). ACE can also cross present antigens. Taken
together, these studies show an emerging and signiﬁcant role for
ACE in the generation of MHC-I-restricted epitopes.
Apart from these exopeptidases, ER endoproteolytic activities
were the ﬁrst non-proteasomal peptidases identiﬁed in antigen
processing in 1992 (Henderson et al., 1992; Wei  and Cresswell,
1992). Signal sequences of secretory and membrane proteins have
a pattern sequence, are 10 to 30 aa in length and their cleavage by
signal peptidase (SP) yields short peptides that need little further
trimming to bind MHC-I. Yet, about half of the MHC-I ligands iden-
tiﬁed so far within them by immunoproteomics require both Nt
and Ct trimming to generate the ﬁnally presented epitope. Excep-
tionally, signal peptidase can generate the exact Ct in ∼75% of the
signal sequence-derived ligands bound to MHC-I HLA-A2, which
easily ﬁts alanine in the Ct position. There are several examples of
TAP-independent epitopes generated by signal peptidase, as well as
others transported by TAP, although some epitopes are destroyed.
In addition, signal peptidase can process exogenous antigens for
cross presentation.
The signal peptide peptidase (SPP) is another ER resident
endopeptidase that cleaves within transmembrane domains and
inside some signal sequences. It is involved in the processing and
presentation of a proteasome and TAP-dependent epitope (Bland
et al., 2003) and in the liberation of a Ct peptide that is presented
independently of TAP.
4. Endopeptidases and aminopeptidase in the distal
secretory pathway associated with antigen processing
Unlike the cytosol or lysosomes, the secretory pathway and
most vesicular compartments are poorly degradative. However,
there are different endopeptidases that participate in MHC-I anti-
gen processing. As in the cytosol, these endopeptidases often can
process antigens independently of proteasomes and, in this case,
also of TAP.
Furin is a trans-Golgi network proprotein convertase mediat-
ing the maturation of peptidic hormones and factors, and viral
and cellular glycoproteins. It participates in antigen processing
of TAP-independent epitopes, both after direct presentation from
endogenous proteins (Gil-Torregrosa et al., 1998; Medina et al.,
2009; Tiwari et al., 2007) and after cross presentation of cell-
penetrating peptides. Although more efﬁcient in TAP-deﬁcient
cells, furin can contribute to generating around 1/3 of the molecules
of a given peptide/MHC-I complex in TAP+ cells, showing that this
peptidase takes part in global antigen presentation in the presence
of TAP. Furin-processed antigens targeted to the secretory route
elicit functional CD8+ T lymphocytes in TAP1−/− mice (Medina et al.,
2009).
Cathepsins are located in endolysosomal compartments.
Together with furin, cathepsins are involved through a vacuolar
TAP-independent pathway in generation and direct presentation of
an epitope (Tiwari et al., 2007) and speciﬁcally cathepsin S in cross
presentation of another one in phagosomes (Shen et al., 2004).
Proprotein convertase 7 (PC7) is located in the trans-Golgi net-
work and in endocytic vesicles, it globally stabilizes unstable MHC-I
molecules that are sub-optimally loaded in the absence of TAP,
and processes a short precursor peptide. This provides a second
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quality check-point for loading new peptides onto MHC  molecules
(Leonhardt et al., 2010).
Finally, insulin-regulated aminopeptidase (IRAP), related to ERAPs
but located in a speciﬁc endosomal compartment, can cross present
epitopes in cell culture and in vivo, although it is not involved in
direct antigen presentation (Saveanu et al., 2009).
5. Concluding remarks
The nucleo-cytosolic proteasome is recognized as a relevant
peptidase that generates antigenic peptide precursors for MHC-I,
although this is not its major function in the cell. Both assertions
apply also to ∼20 other peptidases, which are located in the cytosol,
ER and more distal secretory route. Among them, exopeptidases
trimming Nt or Ct of epitope precursors cooperate with protea-
somes, while endopeptidases commonly can generate epitopes
independently of proteasomes. Exopeptidases and endopeptidases,
especially but not exclusively those located in the ER or vesic-
ular compartments, equally contribute to cross presentation of
exogenous antigens. A single recently-identiﬁed carboxypeptidase
stands out. Deeper knowledge of new non-proteasomal peptidases
and carboxypeptidases involved in these processes is likely to
attract much research effort for years to come. Use of chemical
inhibitors, interference RNA, and CRISPR technology will allow the
understanding of their mechanisms and speciﬁcity. Knowledge on
the generation of epitopes that are presented at the cell surface
to CD8+ T cells will contribute to the design of new epitope-based
vaccines against infections by viruses and intracellular bacteria. In
addition, knowing how to proﬁt from all proteolytic activities also
in tumor cells may  contribute to potentiating the immunogenic-
ity of tumors, and thus contribute to the exciting success of novel
stimulatory T-lymphocyte-based immunotherapies of cancer.
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